OP Asset Management Ltd purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 20,869 shares of the company’s stock, valued at approximately $11,726,000.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $26,000. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the third quarter worth approximately $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the fourth quarter worth approximately $29,000. WealthCollab LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in IDEXX Laboratories during the 3rd quarter worth approximately $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on the stock. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target for the company. Finally, Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.
IDEXX Laboratories Stock Performance
Shares of IDXX stock opened at $549.16 on Thursday. The stock’s 50-day moving average is $559.95 and its two-hundred day moving average is $616.34. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The firm has a market cap of $43.32 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 2.96 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
